Cell News and Research

RSS

Online resources on AI and cancer lack quality, need improvement

Online information about artificial intelligence (AI) and its impact on cancer research and treatment for both the patient and general-public audiences is limited, and the available webpages and videos are largely of low quality, difficult to read, and frequently omit risks of AI use, according to new research presented today at the at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9000) and led by researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn's Perelman School of Medicine.

1 Jun 2026

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).

1 Jun 2026

Mesenchymal drift may explain how aging cells lose their identity

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.

1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

Novel PRRT approach shows promise in advanced neuroendocrine tumors

A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.

31 May 2026

Researchers uncover new clues about the origin of Alzheimer's tau tangles

Researchers at Columbia University have uncovered new clues about the earliest molecular events that may trigger Alzheimer's disease, shedding light on how toxic tau filaments begin to form in the brain.

29 May 2026

Teclistamab delivers deeper responses in relapsed myeloma patients

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

29 May 2026

Gladstone scientists track exact routes used to clear brain waste

Think of the brain as if it were a house. Insulated from its environment, a house relies on complex networks-pipes, drains, and disposal systems-that interface with the outside world to keep the home functional on the inside.

29 May 2026

RNA therapy targets genetic cause of heart failure in the Netherlands

Using patient-derived cardiac tissue and stem cell-based models, the team of translational researchers demonstrated that targeting the genetic cause of disease improved cellular abnormalities and identified the biological pathways involved.

29 May 2026

Review explores diagnosis and management of perioperative anaphylaxis during anesthesia

Perioperative anaphylaxis is a rare, life‑threatening condition during anesthesia. The unique setting – multiple drugs, patient draping, and altered physiology – causes higher mortality than anaphylaxis elsewhere.

29 May 2026

Review explores complex associations between sleep apnea and lung cancer

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent hypoxia and sleep fragmentation, which may contribute to lung cancer development and progression.

29 May 2026

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.

29 May 2026

Novel therapeutic agent proposed to combat drug resistant tuberculosis

A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques.

29 May 2026

New approach helps design better antibiotics to fight drug-resistant infections

A new way of designing antibiotics could support the discovery of new treatments for drug-resistant infections.

29 May 2026

4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.

From 4basebio PLC 29 May 2026

Could guava juice help prevent anemia?

Guava juice intake is linked to increased hemoglobin levels in females, highlighting its role as a dietary complement to traditional iron supplementation.

29 May 2026

Sino Biological’s Cell-Free Protein Synthesis supports Tencent AI for Life Sciences Lab’s protein design study published in Nature Communications

Sino Biological, Inc. has announced that its gene synthesis and cell-free protein expression workflow was used in a recent study by Tencent AI for Life Sciences Lab published in Nature Communications, enabling rapid validation of AI-designed proteins with improved activity, stability, and multifunctionality

From Sino Biological Inc. 29 May 2026

Harnessing human brain cells to create biocomputers

JMIR Publications today released a feature story on the emerging field of biocomputing in its News and Perspectives section.

29 May 2026

Scientists uncover shared gene signatures that reveal how mammals age

Researchers mapped more than 11,000 transcriptomes across mice, rats, macaques, and humans, revealing conserved molecular signatures of aging and mortality across tissues, species, and cell types. The study developed interpretable transcriptomic clocks that track age, mortality-related molecular change, chronic disease signals and responses to lifespan-altering interventions.

29 May 2026